
Senior Director, R&D Quality Assurance (GCP-GLP-GvP)
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. By leveraging multiple moda
Senior Director, R&D Quality Assurance (GCP-GLP-GvP)
Senior Manager/Associate Director, Clinical Data Management
Manage all clinical data management aspects from start-up and database design through close-out and archival of studies Act as lead Clinical Data Manager on one or multiple clinical trials Oversee all activities outsourced to clinical research organizations, including review and approval of key deli
Senior Manager/Associate Director, Clinical Data Management
Director, Translational Medicine
Develop and execute translational strategy to help advance Crescent’s clinical pipeline Provide oversight of the development, validation, and execution of fit-for-purpose clinical biomarker assays with external CROs and actively manage vendor relationships Drive clinical biomarker sample testing and
Vice President, Program Team Leader
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. By leveraging multiple moda
Vice President, Program Team Leader
Director, Clinical Pharmacology
Serve as the lead clinical pharmacologist on the project team, accountable for clinical pharmacology deliverables, providing subject matter expertise on PK/PD and quantitative pharmacology. Play a pivotal role in planning and executing clinical pharmacology activities to support development programs
Director, Clinical Pharmacology
Executive Director/Vice President, Medical Lead
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. By leveraging multiple moda